Tender Offer - LUMOS PHARMA, INC.

Form Type: CORRESP

Filing Date: 2024-11-29

Corporate Action: Tender-offer

Type: Update

Accession Number: 000119312524268143

Filing Summary: Lumos Pharma, Inc. filed a correspondence letter on November 29, 2024, in response to comments from the SEC staff regarding their Schedule 14D-9 filed on November 14, 2024. The letter addresses the need for Lumos to provide full financial projections rather than a summary in light of potential payments to shareholders from a contingent value right (CVR) tied to the company's future operations. This change has been incorporated in Amendment No. 1 to the Schedule 14D-9. Additionally, the letter responds to a comment about the removal of a reference to safe harbor provisions related to forward-looking statements, which do not apply to tender offers. The correspondence includes the names of various company representatives and their counsel for any further inquiries.

Document Link: View Document